2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

2013 Symposium Photos

2012 Featured Talks

2012 Symposium Photos

2011 Featured Talks

2011 Symposium Photos

Past Symposia in the Press

2013 Featured Talks » Cancer Treatment with NK Cell Lines: An Effective Alternative?



Cancer Treatment with NK Cell Lines: An Effective Alternative?


Armand Keating, MD, FCRP(C), University of Toronto, Princess Margaret Hospital

» Download Audio









Armand Keating, MD, FCRP(C), is Professor of Medicine, Director, Division of Hematology, Epstein Chair in Cell Therapy and Transplantation and a Professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, Toronto, Canada. He is also Director of the Cell Therapy Program and the Orsino Cell Therapy Translational Research Laboratory at Princess Margaret Hospital and a Senior Scientist in Experimental Therapeutics at the Toronto General Research Institute.

He obtained the MD degree from the University of Ottawa, completed residencies in internal medicine and hematology at the University of Toronto and a research fellowship at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, Washington. He was a Cancer Research Scientist of the National Cancer Institute of Canada for 10 years and upon his return to Toronto established the largest stem cell transplant program in Canada. He was Chief of Medical Services and Head, Department of Medical Oncology and Hematology at Princess Margaret Hospital/Ontario Cancer Institute in Toronto for a decade. He is listed in Best Doctors in Canada and the US. Over the past 7 years he established the largest and most active cell therapy program in Canada involving local, national and international collaborators. He is the recipient of a multimillion dollar Canada Foundation for Innovation Award for a regional Center for Cell and Vector Production in Toronto.

Dr. Keating has been active in the American Society of Hematology (ASH) having served as a Councilor and Secretary and was President of ASH in 2012. He is a past president of the American Society for Blood and Marrow Transplantation and was Chair of the Steering Committee for Cell-Based Therapy of the National Heart, Lung, and Blood Institute, US National Institutes of Health. He was also Chair of the Medical and Scientific Committee of The Leukemia & Lymphoma Society and a member of its Board of Directors for 8 years. He heads the Clinical Translation Committee of the International Society for Stem Cell Research (ISSCR). He is a member of the Canadian Stem Cell Network and is on the advisory boards of the Argentine Stem Cell Consortium and the Andalusian Advanced Therapies Program. He is on numerous editorial boards of scholarly journals, and is a Co-Editor of Bone Marrow Transplantation and Associate Editor of Biology of Blood and Marrow Transplantation.

Dr. Keating’s clinical and research interests focus on anti-cancer cell therapy, blood and marrow transplantation, leukemia, lymphoma, and cell-based tissue regeneration. He has conducted laboratory, translational and clinical research in cell therapy, normal and leukemic hematopoiesis, and on the biology and clinical application of mesenchymal stromal cells. He has authored over 360 publications.